rmdopen.bmj2d
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads ...
rmdopen.bmj2d
Getting prepared for the silver wave: challenges in conducting rheumatic and musculoskeletal disease research in older adults
Research in older adults diagnosed with rheumatic and musculoskeletal diseases (RMDs) comes with unique challenges, as these patients often face consequences of ageing, such as multimorbidity, ...
rmdopen.bmj3d
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, ...
rmdopen.bmj4d
Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis
Objectives Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is linked to high mortality. Currently, ...
rmdopen.bmj7d
Targeting the IL-17A pathway for therapy in early-stage tendinopathy
Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic ...
rmdopen.bmj8d
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
Objectives To evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS).
rmdopen.bmj25d
Chronic kidney disease in patients with psoriatic arthritis: a cohort study
Objectives Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). We aimed to define the prevalence of CKD in patients with PsA, describe their long-term renal outcomes and ...
rmdopen.bmj25d
Immune checkpoint molecules performance in ANCA vasculitis
Objective The PD-1 axis promotes protection against autoimmunity. Immune checkpoint (IC) molecules performance in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) remains unknown. This ...
rmdopen.bmj27d
Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
Objectives A few studies on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatments have shown the therapeutic efficacy of mycophenolate mofetil (MMF). However, the ...
rmdopen.bmj27d
Metabolomic profiles, polygenic risk scores and risk of rheumatoid arthritis: a population-based cohort study in the UK Biobank
Objective To investigate the relationship between metabolomic profiles, genome-wide polygenic risk scores (PRSs) and risk of rheumatoid arthritis (RA). Methods 143 nuclear magnetic resonance-based ...
rmdopen.bmj27d
Artificial intelligence in rheumatology research: what is it good for?
Artificial intelligence (AI) is transforming rheumatology research, with a myriad of studies aiming to improve diagnosis, prognosis and treatment prediction, while also showing potential capability to ...